| Year |
Citation |
Score |
| 2015 |
Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Zhang X, Setze C, Rodrigues L, Burroughs M, Redman R, Chayama K, Kumada H, Collins C, Pilot-Matias T. Analysis of HCV Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir/Ritonavir and Ombitasvir. Antimicrobial Agents and Chemotherapy. PMID 26643326 DOI: 10.1128/AAC.02606-15 |
1 |
|
| 2015 |
Schnell G, Tripathi R, Beyer J, Reisch T, Krishnan P, Lu L, Dekhtyar T, Hall C, Vilchez RA, Pilot-Matias T, Collins C. Hepatitis C Virus Genotype 4 Resistance and Subtype Demographic Characterization of Patients Treated with Ombitasvir plus Paritaprevir/ritonavir. Antimicrobial Agents and Chemotherapy. PMID 26282418 DOI: 10.1128/AAC.01229-15 |
1 |
|
| 2015 |
Krishnan P, Tripathi R, Schnell G, Reisch T, Beyer J, Irvin M, Xie W, Larsen L, Cohen D, Podsadecki T, Pilot-Matias T, Collins C. Resistance Analysis of Baseline and Treatment-Emergent Variants in the AVIATOR Study With Paritaprevir/r, Ombitasvir and Dasabuvir in HCV Genotype 1. Antimicrobial Agents and Chemotherapy. PMID 26100711 DOI: 10.1128/AAC.00998-15 |
1 |
|
| 2015 |
Kati W, Koev G, Irvin M, Beyer J, Liu Y, Krishnan P, Reisch T, Mondal R, Wagner R, Molla A, Maring C, Collins C. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrobial Agents and Chemotherapy. 59: 1505-11. PMID 25534735 DOI: 10.1128/AAC.04619-14 |
1 |
|
| 2015 |
Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, DeGoey D, Kati W, Campbell A, Williams L, Xie W, Setze C, Molla A, Collins C, Pilot-Matias T. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrobial Agents and Chemotherapy. 59: 979-87. PMID 25451055 DOI: 10.1128/AAC.04226-14 |
1 |
|
| 2014 |
DeGoey DA, Randolph JT, Liu D, Pratt J, Hutchins C, Donner P, Krueger AC, Matulenko M, Patel S, Motter CE, Nelson L, Keddy R, Tufano M, Caspi DD, Krishnan P, et al. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. Journal of Medicinal Chemistry. 57: 2047-57. PMID 24400777 DOI: 10.1021/jm401398x |
1 |
|
| 2013 |
DeGoey DA, Betebenner DA, Grampovnik DJ, Liu D, Pratt JK, Tufano MD, He W, Krishnan P, Pilot-Matias TJ, Marsh KC, Molla A, Kempf DJ, Maring CJ. Discovery of pyrido[2,3-d]pyrimidine-based inhibitors of HCV NS5A. Bioorganic & Medicinal Chemistry Letters. 23: 3627-30. PMID 23642966 DOI: 10.1016/j.bmcl.2013.04.009 |
1 |
|
| 2012 |
Peters-Libeu C, Miller J, Rutenber E, Newhouse Y, Krishnan P, Cheung K, Hatters D, Brooks E, Widjaja K, Tran T, Mitra S, Arrasate M, Mosquera LA, Taylor D, Weisgraber KH, et al. Disease-associated polyglutamine stretches in monomeric huntingtin adopt a compact structure. Journal of Molecular Biology. 421: 587-600. PMID 22306738 DOI: 10.1016/j.jmb.2012.01.034 |
1 |
|
| 2011 |
Miller J, Arrasate M, Brooks E, Libeu CP, Legleiter J, Hatters D, Curtis J, Cheung K, Krishnan P, Mitra S, Widjaja K, Shaby BA, Lotz GP, Newhouse Y, Mitchell EJ, et al. Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nature Chemical Biology. 7: 925-34. PMID 22037470 DOI: 10.1038/nchembio.694 |
1 |
|
| 2008 |
He Y, King MS, Kempf DJ, Lu L, Lim HB, Krishnan P, Kati W, Middleton T, Molla A. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrobial Agents and Chemotherapy. 52: 1101-10. PMID 18086851 DOI: 10.1128/AAC.01149-07 |
1 |
|
| 2007 |
Tripathi RL, Krishnan P, He Y, Middleton T, Pilot-Matias T, Chen CM, Lau DT, Lemon SM, Mo H, Kati W, Molla A. Replication efficiency of chimeric replicon containing NS5A-5B genes derived from HCV-infected patient sera. Antiviral Research. 73: 40-9. PMID 16914212 DOI: 10.1016/j.antiviral.2006.07.005 |
1 |
|
| 2005 |
Peters-Libeu C, Newhouse Y, Krishnan P, Cheung K, Brooks E, Weisgraber K, Finkbeiner S. Crystallization and diffraction properties of the Fab fragment of 3B5H10, an antibody specific for disease-causing polyglutamine stretches. Acta Crystallographica. Section F, Structural Biology and Crystallization Communications. 61: 1065-8. PMID 16511236 DOI: 10.1107/S1744309105036547 |
1 |
|
| 2001 |
Krishnan P, Bastow KF. Novel mechanism of cellular DNA topoisomerase II inhibition by the pyranonaphthoquinone derivatives alpha-lapachone and beta-lapachone. Cancer Chemotherapy and Pharmacology. 47: 187-98. PMID 11320661 DOI: 10.1007/s002800000221 |
1 |
|
| 2000 |
Krishnan P, Bastow KF. The 9-position in berberine analogs is an important determinant of DNA topoisomerase II inhibition. Anti-Cancer Drug Design. 15: 255-64. PMID 11200501 |
1 |
|
| 2000 |
Krishnan P, Bastow KF. Novel mechanisms of DNA topoisomerase II inhibition by pyranonaphthoquinone derivatives-eleutherin, alpha lapachone, and beta lapachone. Biochemical Pharmacology. 60: 1367-79. PMID 11008131 DOI: 10.1016/S0006-2952(00)00437-8 |
1 |
|
| 2000 |
Tachibana Y, Zhu XK, Krishnan P, Lee KH, Bastow KF. Characterization of human lung cancer cells resistant to 4'-O-demethyl-4beta-(2"-nitro-4"-fluoroanilino)-4-desoxypodophyllotoxin , a unique compound in the epipodophyllotoxin antitumor class. Anti-Cancer Drugs. 11: 19-28. PMID 10757559 DOI: 10.1097/00001813-200001000-00004 |
1 |
|
| Show low-probability matches. |